Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study shows valbenazine may ease uncontrollable movements in mental health patients

NCT ID NCT05859698

First seen Jan 19, 2026 · Last updated Jun 16, 2026 · Updated 22 times

Summary

This study looked at how well valbenazine works for tardive dyskinesia, a condition causing uncontrollable movements often linked to psychiatric medications. 59 adults with schizophrenia, bipolar disorder, or depression took valbenazine for up to 24 weeks. Researchers measured changes in quality of life, daily functioning, and overall health to see if the drug helped reduce the impact of the movement disorder.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Neurocrine Clinical Site

    Bryant, Arkansas, 72022, United States

  • Neurocrine Clinical Site

    Anaheim, California, 92805, United States

  • Neurocrine Clinical Site

    Orange, California, 92868, United States

  • Neurocrine Clinical Site

    Torrance, California, 90504, United States

  • Neurocrine Clinical Site

    Bonita Springs, Florida, 34134, United States

  • Neurocrine Clinical Site

    Miami, Florida, 33176, United States

  • Neurocrine Clinical Site

    Miami Lakes, Florida, 33016, United States

  • Neurocrine Clinical Site

    Okeechobee, Florida, 34972, United States

  • Neurocrine Clinical Site

    Tampa, Florida, 33629, United States

  • Neurocrine Clinical Site

    Atlanta, Georgia, 30328, United States

  • Neurocrine Clinical Site

    Augusta, Georgia, 30912, United States

  • Neurocrine Clinical Site

    Marietta, Georgia, 30060, United States

  • Neurocrine Clinical Site

    Lincoln, Nebraska, 68526, United States

  • Neurocrine Clinical Site

    Beechwood, Ohio, 44122, United States

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma, 73112, United States

  • Neurocrine Clinical Site

    DeSoto, Texas, 75115, United States

  • Neurocrine Clinical Site

    El Paso, Texas, 79902, United States

  • Neurocrine Clinical Site

    Houston, Texas, 77030, United States

Conditions

The condition(s) this trial relates to.

bipolar disorder major depressive disorder Psychotic Disorders schizoaffective disorder schizophrenia tardive dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.